StocksMedium•3 November 2026•
1 min read
Cardiol Therapeutics Launches $75M At-The-Market Equity Program via Jefferies
Key Facts
1Cardiol Therapeutics entered into a sales agreement with Jefferies LLC to launch an at-the-market (ATM) equity offering program.
2The program allows the company to offer and sell common shares up to an aggregate value of US$75 million.
Cardiol Therapeutics entered into a sales agreement with Jefferies LLC to launch an at-the-market (ATM) equity offering program. PR Newswire reported that the program allows the company to offer and sell common shares up to an aggregate value of US$75 million.
The company intends to use the net proceeds to support the development of CardiolRx for the treatment of recurrent pericarditis, as well as the clinical development of CRD-38 and general administrative expenses. CRDL closed at $1.04 on November 2, 2026, with a daily trading range between $1.03 and $1.12 during that session.